Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
of cellular senescence, including senescence in stem cells, and identifying novel approaches to reduce the senescent cell burden. The candidate will join an exciting research environment in
-
, optogenetics, genome engineering, induced pluripotent stem cell differentiation to neurons/organoids, and in vitro and in vivo electrophysiological measurements. Our long-term scientific goal is to dissect
-
topics. Each focuses on gene regulation – and changes that occur in gene regulation – during stem cell development and differentiation. We use mice to model pediatric malignancies. The overall goal of our
-
models using induced pluripotent stem cell (iPSC)-derived kidney organoids. A key aspect of this work will involve integrating bioprinting and organ-on-chip technologies to create mature and
-
histological techniques on tissues and/or cells (protein extraction, preparation of histological samples, Western blotting, ELISA); -Experience with cell culture techniques (stem cells and primary osteoblasts
-
- and stem cell biology, and great synergy with renowned research groups. More information on the IMMENS and open positions available at the Åbo Akademi University in Turku can be found here: https
-
state-of-the-art facilities, cutting-edge expertise in vascular-, tumor-, immunological- and stem cell biology, and great synergy with renowned research groups. More information on the IMMENS and open
-
-edge research across diverse disciplines such as stem cell biology, aging and neurodegeneration, sleep, neurodevelopment, psychotic disorders, and precision health. Our department is also collaborating
-
genomics, transcriptomics, and epigenomics with mechanistic studies using in vitro and in vivo models to dissect B-ALL and related hematologic malignancies. The lab also studies normal hematopoietic stem
-
researchers are dedicated to improving outcomes for all patients. The MM program is renowned for its clinical and research excellence. We have experience with conventional therapies, autologous stem cell